DUBLIN, Sept. 12, 2017 /PRNewswire/ -- Today,
Allergan plc (NYSE: AGN) announced that the Company is launching
the next generation of its groundbreaking U.S.-based Brilliant
Distinctions® program. The new offering incorporates the
latest in digital innovation to enhance the consumer experience and
drive increased member engagement. In addition, Brilliant
Distinctions® is also expanding to include the latest
addition to the Allergan aesthetic portfolio,
CoolScuplting®, in the body treatments category.
CoolSculpting® non-invasively freezes fat in indicated
body areas to help eliminate unwanted visible fat bulges. In the
facial aesthetics category, the program provides savings to
patients for loyalty and frequency of treatments and products, such
as BOTOX® Cosmetic (onabotulinumtoxinA), the
JUVÉDERM® Collection of Fillers, the
SkinMedica® cosmetic skincare line, and
Latisse® (bimatoprost ophthalmic solution) 0.03%.
"When Allergan launched Brilliant Distinctions®
in 2009, we were the first aesthetic company to offer
a patient savings and loyalty program. A true
category innovation, the program serves more than three million
members nationwide," said Jim
Umberger, Vice President, Digital/Multi-Channel Marketing,
US Medical Aesthetics for Allergan. "As the aesthetic category
leader, we are committed to enhancing the consumer experience and
have invested in cutting edge technology to create the next
generation of the Brilliant Distinctions® program, with
an even greater focus on providing savings to our consumers. We're
also very pleased to be adding CoolSculpting® to the
program, which will offer members even more ways to earn and redeem
savings on the Allergan treatments and products they, and their
doctors, have come to know and trust."
The re-launch also marks the rollout of a best in-class
e-commerce platform, Brilliant Connections™, which
offers patients the convenience of purchasing
SkinMedica® products online. The platform's introduction
aims to help physicians meet the evolving needs of their patients
by allowing them the option of purchasing their recommended
SkinMedica® regimen whenever and wherever they want.
Through Brilliant Connections™ users will also earn
Brilliant Distinctions® savings and have the option to
enroll in a subscription service to automatically replenish
products as needed.
Upgraded features of the Brilliant Disctinctions®
program include:
- Updated mobile app makes earning and tracking points
easy and allows members to shop for SkinMedica® products
through participating providers - anytime, anywhere
- New tiered system assigns consumers Silver, Gold, or
Diamond status based on activity
- Generous expiration period means points stay valid
longer and are easier to redeem at participating doctors'
offices
- User-friendly online dashboard displays a comprehensive
overview of earnings and current point totals
"My patients are always asking how they can save money on the
Allergan aesthetic treatments they use regularly, so I'm happy to
be able to share the new Brilliant Distinctions® program
with them," said Deborah Sherman,
MD. "The program is easy for my staff to use, and my patients enjoy
the benefits, which rewards them with savings for being faithful to
our recommended treatments."
To join Brilliant Distinctions® and start earning
points toward your Allergan aesthetic treatments and product
purchases visit www.brilliantdistinctionsprogram.com, and download
the app on iTunes or Google Play.
BOTOX® Cosmetic (onabotulinumtoxinA) Important
Information
Approved Uses
BOTOX® Cosmetic is a prescription medicine that is
injected into muscles and used to temporarily improve the look of
both moderate to severe crow's feet lines and frown lines between
the eyebrows in adults.
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects
that can be life threatening. Get medical help right away if you
have any of these problems any time (hours to weeks) after
injection of BOTOX® Cosmetic:
- Problems swallowing, speaking, or breathing, due to
weakening of associated muscles, can be severe and result in loss
of life. You are at the highest risk if these problems are
pre-existing before injection. Swallowing problems may last for
several months
- Spread of toxin effects. The effect of botulinum
toxin may affect areas away from the injection site and cause
serious symptoms including: loss of strength and all-over muscle
weakness, double vision, blurred vision and drooping eyelids,
hoarseness or change or loss of voice, trouble saying words
clearly, loss of bladder control, trouble breathing, trouble
swallowing
BOTOX® Cosmetic dosing units are not the same
as, or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin
effect when BOTOX® Cosmetic has been used at the
recommended dose to treat frown lines, crow's feet lines, or both
at the same time.
BOTOX® Cosmetic may cause loss of strength or
general muscle weakness, vision problems, or dizziness within hours
to weeks of taking BOTOX® Cosmetic. If this
happens, do not drive a car, operate machinery, or do other
dangerous activities.
Serious and/or immediate allergic reactions have been
reported. They include: itching, rash, red itchy welts,
wheezing, asthma symptoms, or dizziness or feeling faint. Get
medical help right away if you are wheezing or have asthma
symptoms, or if you become dizzy or faint.
Do not take BOTOX® Cosmetic if
you: are allergic to any of the ingredients in
BOTOX® Cosmetic (see Medication Guide for
ingredients); had an allergic reaction to any other botulinum toxin
product such as
Myobloc® (rimabotulinumtoxinB),
Dysport® (abobotulinumtoxinA), or
Xeomin® (incobotulinumtoxinA); have a skin
infection at the planned injection site.
Tell your doctor about all your muscle or nerve
conditions, such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton
syndrome, as you may be at increased risk of serious side effects
including difficulty swallowing and difficulty breathing from
typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical
conditions, including: plans to have surgery; had surgery
on your face; weakness of forehead muscles: trouble raising your
eyebrows; drooping eyelids; any other abnormal facial change; are
pregnant or plan to become pregnant (it is not known if
BOTOX® Cosmetic can harm your unborn baby); are
breast-feeding or plan to (it is not known if
BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you
take, including prescription and nonprescription
medicines, vitamins, and herbal products. Using
BOTOX® Cosmetic with certain other medicines may
cause serious side effects. Do not start any new medicines
until you have told your doctor that you have received
BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin
product in the last 4 months; have received injections of botulinum
toxin such as Myobloc®, Dysport®, or
Xeomin® in the past (tell your doctor exactly which
product you received); have recently received an antibiotic by
injection; take muscle relaxants; take an allergy or cold medicine;
take a sleep medicine; take aspirin-like products or blood
thinners.
Other side effects of BOTOX® Cosmetic
include: discomfort or pain at the injection site;
headache; and eye problems: double vision, blurred vision, drooping
eyelids, and swelling of your eyelids.
For more information refer to the Medication Guide or talk with
your doctor.
To report a side effect, please call Allergan at
1-800-678-1605.
Please see BOTOX® Cosmetic
full Product Information including Boxed
Warning and Medication Guide.
JUVÉDERM® Injectable Gel Fillers Important
Information
APPROVED USES
JUVÉDERM VOLUMA® XC injectable gel is for deep
injection in the cheek area to correct age-related volume loss in
adults over 21.
JUVÉDERM® XC and JUVÉDERM VOLLURE™ XC
injectable gels are for injection into the facial tissue for the
correction of moderate to severe facial wrinkles and folds, such as
nasolabial folds. JUVÉDERM VOLLURE™ XC injectable gel is
for adults over 21.
JUVÉDERM® Ultra XC is for injection into the lips and
perioral area for lip augmentation in adults over 21.
JUVÉDERM VOLBELLA® XC injectable gel is for injection
into the lips for lip augmentation and for correction of perioral
lines in adults over 21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any
JUVÉDERM® injectable gel formulation?
Do not use these products if you have a history of multiple
severe allergies or severe allergic reactions (anaphylaxis), or if
you are allergic to lidocaine or the Gram-positive bacterial
proteins used in these products.
What precautions should my doctor advise me about?
- Tell your doctor if you are pregnant or breastfeeding. The
safety of these products for use during pregnancy or while
breastfeeding has not been studied
- The safety of JUVÉDERM VOLUMA® XC in patients under
35 years or over 65 years, the safety of JUVÉDERM® XC
and JUVÉDERM® Ultra XC injectable gels in patients under
18 years, and the safety of JUVÉDERM VOLLURE™ XC and
JUVÉDERM VOLBELLA® XC in patients under 22 years has not
been studied
- The safety and effectiveness of JUVÉDERM VOLUMA® XC
in areas other than the cheek area, JUVÉDERM® XC and
JUVÉDERM VOLLURE™ XC for areas other than facial
wrinkles and folds, and JUVÉDERM® Ultra XC and JUVÉDERM
VOLBELLA® XC in areas other than the lips and perioral
area have not been established in clinical studies
- Tell your doctor if you have a history of excessive scarring
(eg, hypertrophic scarring and keloid formations) or pigmentation
disorders, as use of these products may result in additional scars
or changes in pigmentation
- Tell your doctor if you are planning other laser treatments or
a chemical peel, as there is a possible risk of inflammation at the
treatment site if these procedures are performed after
treatment
- Patients who experience skin injury near the site of injection
with these products may be at a higher risk for side effects
- Tell your doctor if you are on immunosuppressive therapy used
to decrease the body's immune response, as use of these products
may result in an increased risk of infection
- Tell your doctor if you are using medications that can prolong
bleeding, such as aspirin, ibuprofen, or other blood thinners, as
this may result in increased bruising or bleeding at the injection
site
- Minimize strenuous exercise, exposure to extensive sun or heat,
and alcoholic beverages within the first 24 hours following
treatment
What are possible side effects?
The most commonly reported side effects with
JUVÉDERM® injectable gels included injection-site
redness, swelling, pain, tenderness, firmness, lumps/bumps,
bruising, discoloration, and itching. For JUVÉDERM
VOLBELLA® XC, dryness was also reported. For JUVÉDERM
VOLUMA® XC, most side effects were moderate and lasted 2
to 4 weeks. For JUVÉDERM® XC, JUVÉDERM
VOLLURE™ XC, and JUVÉDERM® Ultra XC
injectable gels, most side effects were mild or moderate and lasted
14 days or less. For JUVÉDERM VOLBELLA® XC, most side
effects were mild or moderate and lasted 30 days or less.
One of the risks with using these products is unintentional
injection into a blood vessel, and, while rare, the complications
can be serious and may be permanent. These complications, which
have been reported for facial injections, can include vision
abnormalities, blindness, stroke, temporary scabs, or permanent
scarring.
As with all skin injection procedures, there is a risk of
infection.
To report a side effect with any JUVÉDERM®
product, please call Allergan at 1-800-433-8871.
Please visit Juvederm.com or talk to your doctor
for more information.
Available by prescription only.
LATISSE® (bimatoprost ophthalmic solution) 0.03%
Important Information
Approved Use
LATISSE® is an
FDA-approved treatment to grow eyelashes for people with inadequate
or not enough lashes.
Important Safety Information
Do not use
LATISSE® if you are allergic to one of its
ingredients. If you use/used prescription products for eye pressure
problems, use LATISSE® under doctor care. May
cause brown darkening of the colored part of the eye which is
likely permanent. LATISSE® may cause eyelid skin
darkening which may be reversible. Only apply at base of upper
lashes. DO NOT APPLY to lower lid. Hair may grow outside the
treatment area. If you have eye problems/surgery, consult your
doctor. Common side effects include itchy and red eyes. If
discontinued, lashes gradually return to previous appearance.
These are not all the possible side effects of
LATISSE®. For more information, please talk to
your doctor.
Please see LATISSE® full Product
Information.
SkinMedica®
Most of the SkinMedica® products described here
are intended to meet the FDA's definition of a cosmetic product, an
article applied to the human body to cleanse, beautify, promote
attractiveness, and alter appearances. These
SkinMedica® products are not intended to be drug
products that diagnose, treat, cure, or prevent any disease or
condition. These products have not been approved by the FDA and the
statements have not been evaluated by the FDA.
SkinMedica® Total Defense + Repair Broad
Spectrum Sunscreens (SPF 34, SPF 34 Tinted, and SPF 50+), Essential
Defense Broad Spectrum Sunscreens (Everyday Clear SPF 47, Mineral
Shield Tinted SPF 32, and Mineral Shield SPF 35), SkinMedica Daily
Physical Defense® Sunscreen Broad Spectrum SPF 30+,
Environmental Defense Sunscreen™ SPF 50+ with UV ProPlex™, and TNS
Ultimate Daily Moisturizer™ SPF 20 Sunscreen are over-the-counter
drug products which are formulated and marketed pursuant to FDA's
governing regulations set forth at 21 C.F.R. Part 352.
SkinMedica® Acne System, Acne Treatment Lotion,
Purifying Foaming Wash, and Purifying Toner, are over-the-counter
drug products which are formulated and marketed pursuant to FDA's
governing regulations set forth at 21 C.F.R. § 333.301 et seq.
CoolSculpting® Treatment Important
Information
In the US, the CoolSculpting® procedure is
FDA-cleared for the treatment of visible fat bulges in the
submental area, thigh, abdomen and flank, along with bra fat, back
fat, underneath the buttocks (also known as banana roll), and upper
arm. Please talk to your healthcare provider or see full Important
Safety Information for additional information.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry with
65+ mid-to-late stage pipeline programs currently in
development.
Allergan's success is powered by our more than 18,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2016 and Allergan's Quarterly Report on Form 10-Q for the
period ended June 30, 2017. Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS: Allergan:
Investors:
Daphne Karydas
(862) 261-8006
Media:
Mark Marmur
(862) 261-7558
Ember Garrett
(714) 246-3525
View original content with
multimedia:http://www.prnewswire.com/news-releases/allergan-launches-new-brilliant-distinctions-patient-loyalty-program-300518040.html
SOURCE Allergan plc